A randomised, double-blind, multinational study to prevent major vascular events with Ticagrelor compared to Aspirin(ASA) in patients with acute ischaemic stroke or Transient Ischemic Attack (TIA). [SOCRATES - Acute Stroke Or Transient IsChaemic Attack TReated with Aspirin or Ticagrelor and Patients OutcomeS]. - SOCRATES

AstraZeneca AB0 个研究点目标入组 9,600 人开始时间: 2013年12月9日最近更新: 2016年5月2日

研究概览

暂无简介。

•Men or women equal or elder 40 years of age - Either acute ischaemic stroke or
•high-risk TIA as defined here and randomisation occurring within 24 hours after onset of symptoms
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 6800
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2800

•Planned use of antithrombotic therapy in addition to study medication including antiplatelets (eg, open label ASA, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine, prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral thrombin and factor Xa
•inhibitors, bivalirudin, hirudin, argatroban, unfractionated and low molecular weight heparins). - Any history of atrial fibrillation, ventricular aneurysm or suspicion of cardioembolic pathology for TIA or
•stroke. - Planned carotid, cerebrovascular, or coronary revascularisation that requires halting study medication within 7 days of randomisation. - Receipt of any intravenous or intra-arterial thrombolysis
•or mechanical thrombectomy within 24 hours prior to randomisation - History of previous symptomatic non-traumatic intracerebral bleed at any time (asymptomatic microbleeds do not qualify), gastrointestinal (GI) bleed within the past 6 months, or major surgery within 30 days.

发起方